Roll-Over study offers continued benralizumab access for patients who benefit

This study gives ongoing access to benralizumab (Fasenra) for people with asthma, eosinophilic granulomatosis with polyangiitis (EGPA), or hypereosinophilic syndrome (HES) who completed a prior benralizumab trial and still benefit from the drug. About 230 participants will receive continued treatment while researchers monitor long-term safety and side effects. The goal is to keep providing a working therapy and gather more safety data over time.